natgillin/translations-raw huggingface dataset:
In the future, the immune system will be able to make the antibodies more quickly when it is exposed to the bacteria again.
V prihodnosti bo imunski sistem ob ponovni izpostavitvi bakterijam sposoben hitreje tvoriti protitelesa.
Milk can be taken at any time after injection.
Mleko se lahko pomolze kadar koli po injiciranju.
What is the risk associated with Startvac?
Kakšna tveganja so povezana z zdravilom Startvac?
Accidental injection or self-injection could cause severe pain and swelling, particularly if the vaccine is injected into a joint or finger.
Nenamerno injiciranje ali samoinjiciranje lahko povzroči hude bolečine in otekline, zlasti ob injiciranju v sklep ali prst.
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) STARTVAC EPAR summary for the public
EMEA/V/C/130 EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) STARTVAC Povzetek EPAR za javnost
When it is given to a cow, the animal's immune system recognises the bacteria as ‘foreign' and makes antibodies against them.
Če cepivo damo kravi, njen imunski sistem prepozna bakterije kot „tuje“ in začne tvoriti protitelesa proti njim.
The full course of injections should be repeated for every pregnancy.
Celoten sklop injiciranj je treba ponoviti ob vsaki brejosti.
The strengthened immunity reduces the number of cows affected and the severity of clinical signs.
Okrepljena imunost zmanjša število obolelih krav in resnost kliničnih znakov.
In rare cases, this could result in the loss of the affected finger if prompt medical attention is not given.
V izjemnih primerih, če ni zagotovljena takojšnja zdravniška oskrba, lahko to privede do izgube prizadetega prsta.
The antibodies will help to fight the bacteria, preventing mastitis occurring or reducing the severity of its symptoms.
Protitelesa bodo pomagala uničevati bakterije in s tem preprečila pojavljanje mastitisa ali zmanjšala resnost simptomov te bolezni.
What is the time to allow before milk can be taken from the animal for human consumption?
Koliko časa mora preteči, preden se lahko mleko porabi za prehrano ljudi?
Startvac injections did not have any harmful effects on pregnancy or giving birth, or on the cows' calves.
Injekcije zdravila Startvac niso imele škodljivih učinkov na brejost, porod ali teleta krav.
Why has Startvac been approved?
Zakaj je bilo zdravilo Startvac odobreno?
Startvac contains killed forms of two bacteria that normally cause mastitis (Escherichia coli and Staphylococcus aureus).
Zdravilo Startvac vsebuje mrtvi obliki dveh bakterij, ki običajno povzročata mastitis (Escherichia coli in Staphylococcus aureus).
Startvac is a vaccine for cows that contains inactivated (killed) bacteria called Escherichia coli and Staphylococcus aureus.
Zdravilo Startvac je cepivo za krave, ki vsebuje inaktivirani (mrtvi) bakteriji, imenovani Escherichia coli in Staphylococcus aureus.
Startvac is used to strengthen the immunity of whole herds of otherwise healthy dairy cows in herds that are known to have problems due to mastitis (inflammation of the udder due to infection).
Zdravilo Startvac se uporablja za krepitev imunosti celotnih čred sicer zdravih krav molznic v čredah, pri katerih so znani problemi zaradi mastitisa (vnetja vimen zaradi okužbe).
Startvac is given to all healthy cows in a herd, during and after pregnancy.
Zdravilo Startvac se daje vsem zdravim kravam v čredi v obdobju brejosti in po njem.
Vaccination with Startvac also led to an increased number of cows being cured of the infection, a reduction in the number of cows that needed treatment for mastitis, and an increase in the quantity and quality of milk production.
S cepljenjem z zdravilom Startvac se je prav tako povečalo število krav, pri katerih se je okužba ozdravila, zmanjšalo število krav, ki jih je treba zdraviti zaradi mastitisa, ter povečala količina in kakovost proizvodnje mleka.
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Startvac exceed the risks for herd immunisation of healthy cows and heifers, in dairy cattle herds with recurring mastitis problems, to reduce the incidence of sub-clinical mastitis and the incidence and severity of the clinical signs of clinical mastitis caused by Staphylococcus aureus, coliforms and coagulase-negative staphylococci, and recommended that Startvac be given a marketing authorisation.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila Startvac pri imunizaciji čred zdravih krav in telic, v čredah krav molznic, pri katerih se ponavlja problem mastitisa, da se zmanjša pogostnost subkliničnega mastitisa in pogostnost ter resnost kliničnih znakov kliničnega mastitisa, ki jih povzročajo Staphylococcus aureus, koliformne bakterije in koagulaza negativni stafilokoki, večje od z njim povezanih tveganj, in priporočil, da se za zdravilo odobri dovoljenja za promet.
The studies showed that Startvac reduced the number of cows with mastitis due to Staphylococcus aureus and related bacteria and it reduced the severity of the symptoms in the cows that had mastitis.
Študije so pokazale, da je zdravilo Startvac zmanjšalo število krav z mastitisom zaradi bakterije Staphylococcus aureus in sorodnih bakterij, prav tako pa je zmanjšalo resnost simptomov pri kravah, ki so imele mastitis.
What is Startvac used for?
Za kaj se zdravilo Startvac uporablja?
Startvac contains liquid paraffin (a type of mineral oil).
Zdravilo Startvac vsebuje tekoči parafin (vrsta mineralnega olja).
The study compared cows that were given Startvac with those that were given placebo (a dummy vaccine) and looked at the number of cows with mastitis, the severity of mastitis symptoms, and milk production.
V študiji so primerjali krave, ki so prejemale zdravilo Startvac, s tistimi, ki so prejemale placebo (cepivo brez zdravilne učinkovine), ter opazovali število krav z mastitisom, resnost simptomov mastitisa in proizvodnjo mleka.
How has Startvac been studied?
Kako je bilo zdravilo Startvac raziskano?
What is Startvac?
Kaj je zdravilo Startvac?
How does Startvac work?
Kako zdravilo Startvac deluje?
Patients over 65 years of age and patients who reduced liver or kidney function may need a lower starting dose of 5 mg per day.
Bolniki, starejši od 65 let, in bolniki z zmanjšanim delovanjem jeter ali ledvic bodo morda potrebovali nižji začetni odmerek, in sicer 5 mg na dan.
The usual dose range is between 5 and 20 mg per day.
Razpon odmerkov je običajno od 5 do 20 mg na dan.
It is available as orodispersible tablets (5, 7.5, 10, 15 and 20 mg).
Na voljo je v obliki orodisperzibilnih tablet (5 mg, 10 mg, 15 mg in 20 mg).
The recommended starting dose of Olazax Disperzi depends on the disease being treated: 10 mg per day is used in schizophrenia and in the prevention of manic episodes, and 15 mg per day in the treatment of manic episodes, unless it is used with other medicines, in which case the starting dose can be 10 mg per day.
Priporočeni začetni odmerek zdravila Olazax Disperzi je odvisen od bolezni, ki jo zdravimo: odmerek 10 mg na dan se uporablja pri shizofreniji in za preprečevanje maničnih epizod, odmerek 15 mg na dan pa se uporablja pri zdravljenju maničnih epizod, razen ob souporabi drugih zdravil, ko lahko začetni odmerek znaša 10 mg na dan.
The full EPAR for Olazax Disperzi can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Inlyta je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The orodispersible tablets are taken by being placed on the tongue, where they disintegrate in the saliva, or by mixing them in water before swallowing.
Orodisperzibilne tablete se zaužijejo tako, da se položijo na jezik, kjer jih slina raztopi, ali tako, da se pred zaužitjem zmešajo z vodo.
This is a summary of the European public assessment report (EPAR) for Olazax Disperzi.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Olazax Disperzi.
What are the benefits and risks of Olazax Disperzi shown during the studies?
Kakšne koristi in tveganja, povezane z zdravilom Olazax, so se pojavile med študijami?
Olazax Disperzi is also effective in maintaining improvement in patients who have responded to an initial course of treatment.
Zdravilo Olazax Disperzi je učinkovito tudi za vzdrževanje izboljšanja stanja pri bolnikih, ki so se odzvali na začetno zdravljenje.
For more information about treatment with Olazax Disperzi, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Olazax Disperzi preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The European Commission granted a marketing authorisation valid throughout the EU for Olazax Disperzi on 10 December 2009
Evropska komisija je dovoljenje za promet z zdravilom Olazax Disperzi, veljavno po vsej Evropski uniji, izdala 10. decembra 2009.
Because Olazax Disperzi is a generic medicine and is bioequivalent to the reference medicines, its benefit and risk are taken as being the same as the reference medicines.
Ker je zdravilo Olazax Disperzi generično zdravilo in je biološko enakovredno referenčnima zdraviloma, so njegove koristi in tveganja enaki kot pri referenčnih zdravilih.
This means that Olazax Disperzi is similar to ‘reference medicines' already authorised in the European Union (EU) called Zyprexa and Zyprexa Velotab.
To pomeni, da je podobno „referenčnima zdraviloma“, ki sta že odobreni v Evropski uniji (EU), in sicer zdraviloma Zyprexa in Zyprexa Velotab.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Olazax Disperzi.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Olazax Disperzi is also used to treat moderate to severe manic episodes (extremely high mood) in adults.
Zdravilo Olazax Disperzi se uporablja tudi za zdravljenje zmernih do težkih maničnih epizod (izjemno privzdignjeno razpoloženje) pri odraslih.
Other information about Olazax Disperzi
Druge informacije o zdravilu Olazax Disperzi
The Committee recommended that Olazax Disperzi be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Olazax Disperzi izda dovoljenje za promet.
Olazax Disperzi is used to treat adults with schizophrenia.
Zdravilo Olazax Disperzi se uporablja za zdravljenje odraslih s shizofrenijo.
Because Olazax Disperzi is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicines, Zyprexa and Zyprexa Velotab.
Ker je zdravilo Olazax Disperzi generično zdravilo, so bile študije na ljudeh omejene na preskuse, s katerimi se dokazuje, da je biološko enakovredno referenčnima zdraviloma Zyprexa in Zyprexa Velotab.
Olazax Disperzi is a ‘generic medicine'.
Zdravilo Olazax Disperzi je „generično zdravilo“.
The CHMP concluded that, in accordance with EU requirements, Olazax Disperzi has been shown to have comparable quality and to be bioequivalent to Zyprexa and Zyprexa Velotab.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Olanzapine Disperzi primerljivo raven kakovosti kot zdravili Zxprexa in Zyprexa Velotab ter da jima je biološko enakovredno.
Olazax Disperzi is a medicine containing the active substance olanzapine.
Olazax Disperzi je zdravilo, ki vsebuje zdravilno učinkovino olanzapin.
The active substance in Olazax Disperzi, olanzapine, is an antipsychotic medicine.
Zdravilna učinkovina zdravila Olazax Disperzi, olanzapin, je antipsihotično zdravilo.
Why has Olazax Disperzi been approved?
Zakaj je bilo zdravilo Olazax Disperzi odobreno?
What is Olazax Disperzi?
Kaj je zdravilo Olazax Disperzi?
What is Olazax Disperzi used for?
Za kaj se zdravilo Olazax Disperzi uporablja?
How is Olazax Disperzi used?
Kako se zdravilo Olazax Disperzi uporablja?
How does Olazax Disperzi work?
Kako zdravilo Olazax Disperzi deluje?
How has Olazax Disperzi been studied?
Kako je bilo zdravilo Olazax Disperzi raziskano?
Injection equipment should be calibrated and inspected regularly to ensure appropriate dosing of the fish.
Pripomočke za injiciranje je treba redno umerjati in pregledovati, da se zagotovi ustrezno odmerjanje za ribo.
The effect of vaccine on reproductive performance has not been investigated.
Učinkov cepiva na reproduktivno zmogljivost niso preučevali.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 27/06/2017
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum pridobitve dovoljenja za promet: 27/06/2017
Only healthy fish should be vaccinated.
Cepi se lahko le zdrave ribe.
MARKETING AUTHORISATION NUMBER(S) EU/2/16/197/001
ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET EU/2/16/197/001
The excipients listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.
Pomožne snovi, navedene v poglavju 6.1 SPC, tabela 1 (dovoljene snovi) priloge Uredbe Komisije (EU) št. 37/2010 določa, da MRL ni potreben ali pa, kot so uporabljene v tem zdravilu za uporabo v veterinarski medicini, niso vključene v Uredbo(ES) št. 470/2009.
ATCvet code: QI10AX.
oznaka ATC vet: QI10AX
Duration of immunity is approximately 3 months after vaccination (demonstrated under laboratory conditions at a water temperature of 12 ±2 °C).
Imunost traja približno 3 mesece po cepljenju (dokazano pod laboratorijskimi pogoji pri temperaturi vode 12 ±2 °C).
Do not use in clinically diseased groups of fish.
Ne uporabljajte pri klinično obolelih jatah rib.
Needle injuries at the site of injection are common following administration of the vaccine which can persist in up to 5% of fish for at least 90 days, and can be seen both macroscopically and microscopically.
Poškodbe zaradi igle na mestu injiciranja so po dajanju cepiva pogoste in lahko pri 5 % rib trajajo najmanj 90 dni, vidne pa so lahko tako makroskopsko kot mikroskopsko.
CLYNAV stimulates active immunity against salmonid alphavirus subtype 3 (SAV3).
CLYNAV spodbudi aktivno imunost proti salmonidnemu alfavirusu podtipa 3 (SAV3).
For the active immunisation of Atlantic salmon to reduce impaired daily weight gain, and reduce mortality, and cardiac, pancreatic and skeletal muscle lesions caused by pancreas disease following infection with salmonid alphavirus subtype 3 (SAV3).
Za aktivno imunizacijo atlantskega lososa z namenom izboljšanja oslabljenega dnevnega prirasta teže ter zmanjšanja smrtnosti in lezij na srcu, trebušni slinavki in skeletnih mišicah, ki jih povzroča bolezen trebušne slinavke po okužbi s salmonidnim alfavirusom podtipa 3 (SAV3).
Connect the other end of the transfer tubing set to the vaccine injection equipment (gun).
Drugi del kompleta cevja za prenos povežite na opremo za injiciranje zdravila (puška).
Transient changes in swimming behaviour, pigmentation and inappetence are very common and can be observed for up to 2, 7 and 9 days, respectively.
Prehodne spremembe v načinu plavanja, pigmentaciji in neješčnost so zelo pogoste in jih je mogoče opaziti do 2, 7 oz. 9 dni.
Onset of immunity occurs within 399 degree days (mean water temperature in °C multiplied by number of holding days) following vaccination.
Imunost nastopi v 399 dnevnih stopinjah (povprečna temperatura vode v °C, pomnožena s številom dni v bazenu) po cepljenju.
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals) - uncommon (more than 1 but less than 10 animals in 1,000 animals) - rare (more than 1 but less than 10 animals in 10,000 animals) - very rare (less than 1 animal in 10,000 animals, including isolated reports).
Pogostost neželenih učinkov je določena po naslednjem dogovoru: - zelo pogosti (pri več kot 1 živali od 10 živali v teku enega zdravljenja) - pogosti (pri več kot 1, toda manj kot 10 živalih od 100 živali) - občasni (pri več kot 1, toda manj kot 10 živalih od 1000 živali) - redki (pri več kot 1, toda manj kot 10 živalih od 10.000 živali) - zelo redki (pri manj kot 1 živali od 10.000 živali, vključujoč posamezne primere).
Interactions with other medicinal products and other forms of interaction No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product.
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Ni podatkov o varnosti ter učinkovitosti ob uporabi tega cepiva s katerim koli drugim zdravilom za uporabo v veterinarski medicini.
Shake product gently before use.
Zdravilo pred uporabo nežno pretresite.
Special warnings for the target species Do not use in clinically diseased groups of fish.
Posebna opozorila za vsako živalsko vrsto Ne uporabljajte pri klinično obolelih jatah rib.
Name and address of the manufacturer of the biological active substance Elanco Canada Ltd
Ime in naslov izdelovalca biološke zdravilne učinkovine Elanco Canada Limited
Based on a 25 g fish weight a standard 0.5 mm diameter 3mm depth needle is recommended to be used routinely.
Na osnovi rib s težo 25 g je pri redni uporabi priporočeno uporabiti standardno iglo s premerom 0,5 mm za vbode globine 3 mm.
Consideration should be made for the weight of the fish before the final selection is made.
Končno izbiro igle je treba sprejeti ob upoštevanju teže ribe.
CLYNAV contains a supercoiled DNA plasmid which expresses proteins of salmon alphavirus which induces a protective immune response in vaccinated Atlantic salmon.
CLYNAV vsebuje dodatno zvito plazmidno DNK , ki izraža beljakovine salmonidnega alfavirusa, kar inducira zaščitni imunski odziv pri cepljenem atlantskem lososu.
Potassium dihydrogen phosphate Disodium hydrogen phosphate heptahydrate Sodium chloride
6.1 Seznam pomožnih snovi kalijev klorid kalijev dihidrogenfosfat heptahidrat natrijevega hidrogenfosfata dinatrijev hidrogenfosfat heptahidrat natrijev klorid prečiščena voda
Anaesthetise the fish to immobilise them, and administer 0.05 ml of the vaccine by intramuscular injection in the area immediately anterior and lateral to the dorsal fin in the epaxial muscle.
Anestezirajte ribo za imobilizacijo in ji dajte 0,05 ml cepiva z intramuskularno injekcijo na mesto, ki je neposredno anteriorno in lateralno glede na hrbtno plavut in epaksialno mišico.
Manufacturer responsible for batch release: Lohmann Animal Health GmbH Heinz-Lohmann-Straβe 4, 27472 Cuxhaven
Izdelovalec, odgovoren za sproščanje serij: Lohmann Animal Health GmbH Heinz-Lohmann-Straβe 4, 27472 Cuxhaven
A minimum body weight of 25 g is recommended at vaccination.
Priporočena telesna teža ob cepljenju je najmanj 25 g.
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with any other veterinary medicinal products.
Zaradi pomanjkanja študij kompatibilnosti tega zdravila za uporabo v veterinarski medicini ne smemo mešati z drugimi zdravili za uporabo v veterinarski medicini.
PARTICULARS TO APPEAR ON THE OUTER PACKAGE CARDBOARD BOX
PODATKI NA ZUNANJI OVOJNINI KARTONSKA ŠKATLA
Transfer tubing kit instructions: using the spiked end, screw the transfer tubing set onto the fill port of the ethyl vinyl acetate (EVA) bag with a ¼ turn in order to secure the line in place.
Navodila za uporabo kompleta cevja za prenos: komplet cevja za prenos privijte s konico na vhod za polnjenje na vrečki iz etilvinilacetata (EVA) ter obrnite za ¼ obrata, da bo linija fiksirana.
Pharmacotherapeutic group: Immunologicals for Atlantic salmon.
Farmakoterapevtska skupina: imunološka zdravila za atlantskega lososa.
TARGET SPECIES Atlantic salmon (Salmo salar).
CILJNE ŽIVALSKE VRSTE Atlantski losos (Salmo salar)
4.11 Withdrawal period(s) Zero degree days.
4.11 Karenca Nič dnevnih stopinj.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each 0.05 ml dose contains:
En 0,05-mililitrski odmerek vsebuje:
Do not mix with any other veterinary medicinal products prior to or during administration.
Pred ali med dajanjem ne mešajte z drugimi zdravili za uporabo v veterinarski medicini.
Personal protective equipment, for example, appropriate protective gloves, should be worn when handling the veterinary product.
Pri ravnanju z zdravilom nosite osebno zaščitno opremo, kot so npr. ustrezne zaščitne rokavice.
Do not use in broodstock.
Ne uporabljajte pri plemenski jati.
Position the needle at 90° in the epaxial muscle, central to the dorsal fin and above the mid-line.
Iglo vbodite pravokotno v epaksialno mišico, centralno na hrbtno plavut in nad vzdolžno osjo.
SPECIAL STORAGE CONDITIONS Store and transport refrigerated (2 °C - 8 °C).
POSEBNA NAVODILA ZA SHRANJEVANJE Shranjujte in prevažajte v hladilniki (2 °C-8 °C).
WITHDRAWAL PERIOD Zero degree days.
Nič dnevnih stopinj.
MANUFACTURER RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. STATEMENT OF THE MRLs
DODATEK II A. IZDELOVALEC BIOLOŠKE ZDRAVILNE UČINKOVINE IN IMETNIK DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJE B. POGOJI DOVOLJENJA ZA PROMET Z ZDRAVILOM TER OMEJITVE GLEDE OSKRBE IN UPORABE C. NAVEDBA NAJVIŠJIH DOVOLJENIH KOLIČIN OSTANKOV ZDRAVILA (MRL)
SPECIAL WARNING(S), IF NECESSARY
KARENCA Karenca: nič dnevnih stopinj POSEBNO(A) OPOZORILO(A), ČE JE/SO POTREBNO(A)
METHOD AND ROUTE(S) OF ADMINISTRATION Intramuscular use.
NAČIN IN POT(I) UPORABE Intramuskularna injekcija Pred uporabo preberite navodilo za uporabo.
NAME OF THE VETERINARY MEDICINAL PRODUCT CLYNAV solution for injection for Atlantic salmon
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI CLYNAV raztopina za injiciranje za atlantskega lososa
250 ml sterile, flexible, ethyl vinyl acetate (EVA) bags with a locking snap down port. A sterile and individually packaged transfer tube set is included in the final product packaging.
250-mililitrsko sterilno, prožna vrečka iz etilvinilacetata (EVA) z odprtino s potisnim poklopcem.
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
IZDELOVALEC BIOLOŠKE ZDRAVILNE UČINKOVINE IN IMETNIK DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJE
EXPIRY DATE EXP {month/year} Once opened use within 10 hours.
Odprto zdravilo uporabite v 10 urah.
No effects other than those described in section 6 have been observed following the administration of an overdose.
Preveliko odmerjanje Po dajanju prevelikega odmerka niso opazili nobenih drugih učinkov, kot tistih opisanih v poglavju
A clear, colourless, particulate-free solution.
FARMACEVTSKA OBLIKA Raztopina za injiciranje Bistra, brezbarvna raztopina brez delcev
Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP.
Zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na ovojnini po EXP. Rok uporabnosti zdravila v pakiranju za prodajo: 2 leti.
Active substance: pUK-SPDV-poly2#1 DNA plasmid coding for salmon pancreas disease virus proteins: 5.1 - 9.4 μg.
Zdravilna učinkovina: plazmidno kodirane DNK pUK-SPDV-poly2#1 beljakovine virusa bolezni trebušne slinavke pri lososu: 5,1-9,4 μg.
QUANTITY OF THE ACTIVE SUBSTANCE(S) Each 0.05 ml dose contains: pUK-SPDV-poly2#1 DNA plasmid coding for salmon pancreas disease virus proteins: 5.1 - 9.4 μg.
KOLIČINA ZDRAVILNE(IH) UČINKOVIN(E) En 0,05-mililitrski odmerek vsebuje: plazmidno kodirane DNK pUK-SPDV-poly2#1 beljakovine virusa bolezni trebušne slinavke pri lososu: 5,1-9,4 μg.
PACKAGE LEAFLET FOR: CLYNAV solution for injection for Atlantic salmon
NAVODILO ZA UPORABO CLYNAV raztopina za injiciranje za atlantskega lososa
Name and address of the manufacturer responsible for batch release
Ime in naslov izdelovalca zdravila, odgovornega za sprostitev serije Lohmann Animal Health GmbH